Edition:
United States

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

144.83USD
4:00pm EDT
Change (% chg)

$-2.13 (-1.45%)
Prev Close
$146.96
Open
$146.65
Day's High
$147.89
Day's Low
$143.99
Volume
80,186
Avg. Vol
169,600
52-wk High
$195.97
52-wk Low
$59.59

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: 2.93
Market Cap(Mil.): $6,857.79
Shares Outstanding(Mil.): 46.66
Dividend: --
Yield (%): --

Financials

  SAGE.OQ Industry Sector
P/E (TTM): -- 108.51 32.45
EPS (TTM): -5.74 -- --
ROI: -34.96 1.61 12.63
ROE: -35.08 0.35 14.80

BRIEF-Sage Therapeutics Reports Quarterly Loss Per Share Of $1.68

* SAGE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON PIPELINE AND PROGRESS TOWARD LAUNCH READINESS

May 03 2018

BRIEF-Sage Therapeutics Submits New Drug Application To U.S. FDA For Intravenous Brexanolone In The Treatment Of Postpartum Depression

* SAGE THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INTRAVENOUS BREXANOLONE IN THE TREATMENT OF POSTPARTUM DEPRESSION

Apr 23 2018

Earnings vs. Estimates